ALPMF — Astellas Pharma, Inc.

Is ALPMF overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - General

Oversold As of October 3, 2026

Astellas Pharma, Inc. (ALPMF) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $14.67. The rating moved from Overbought to Oversold on October 1, 2026.

See all oversold Healthcare stocks →

AI analysis

Astellas Pharma, Inc. (ALPMF) presents a mix of stable cash flows from an established specialty and oncology franchise alongside upside tied to late‑stage biologics and targeted R&D. Current market caution, policy attention on drug pricing and competition in metabolic therapeutics temper near‑term upside, but the company’s diversified portfolio, partnership model and consistent free‑cash generation support relative resilience. Key near‑term drivers include clinical readouts, regulatory decisions, and payer actions, while downside scenarios center on pricing pressure, trial setbacks and FX/supply‑chain disruptions.

Key factors

  • Diversified product portfolio with a strong oncology franchise and established specialty medicines that generate predictable cash flow
  • Ongoing late‑stage biologics and specialty drug R&D that can create selective upside if clinical readouts are positive
  • Defensive demand in risk‑off market environments supports relative stability versus cyclicals
  • Strategic partnerships and licensing (historical collaborations on prostate and other oncology assets) that mitigate single‑asset concentration
  • Prudent balance sheet and steady free cash flow profile compared with smaller biotech peers
  • Exposure to global markets (including U.S. Medicare dynamics) offers scale but also sensitivity to payer negotiation and pricing changes

Risks

  • Heightened policy risk from U.S. Medicare drug‑price negotiation and broader pricing pressure that could compress revenue on higher‑priced therapies
  • Clinical trial failures or regulatory delays for late‑stage candidates would meaningfully hurt sentiment and long‑term growth assumptions
  • Increased competition in metabolic/obesity and specialty therapeutic areas (GLP‑1 and amylin combos) that could alter market share dynamics for some product classes
  • Patent expirations or generic/ biosimilar erosion for established products
  • FX volatility (JPY/USD) and global supply‑chain disruptions that can affect reported results and margins
  • Geopolitical uncertainty and risk‑off flows that reduce investor appetite for cross‑border pharma ADRs
  • Execution risk on manufacturing scale‑up for biologics or combination therapies

See today's live rating, score and targets

Members see the live hourly rating for ALPMF — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.